RCUS logo

Arcus Biosciences, Inc.

RCUS

RCUS: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

more

Show RCUS Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of RCUS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RCUS's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof Jun. 06, 2023
  • Patent Title: Crystalline forms of a cd73 inhibitor and uses thereof May. 16, 2023
  • Patent Title: Oral formulations of cd73 compounds Apr. 25, 2023
  • Patent Title: Dosing with an azolopyrimidine compound Oct. 25, 2022
  • Patent Title: Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2α Aug. 09, 2022
  • Patent Title: Inhibitors of cd73-mediated immunosuppression Mar. 08, 2022
  • Patent Title: Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders Jan. 11, 2022
  • Patent Title: Inhibitors of adenosine 5′-nucleotidase Jul. 13, 2021
  • Patent Title: Quinazoline-pyridine derivatives for the treatment of cancer-related disorders Jun. 29, 2021
  • Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof May. 11, 2021
  • Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof Apr. 20, 2021
  • Patent Title: Azolopyrimidine for the treatment of cancer-related disorders Sep. 03, 2019
  • Patent Title: Modulators of 5′-nucleotidase, ecto and the use thereof Mar. 26, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of RCUS in WallStreetBets Daily Discussion

RCUS News

Recent insights relating to RCUS

CNBC Recommendations

Recent picks made for RCUS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RCUS

Corporate Flights

Flights by private jets registered to RCUS